Pathology Laboratory Services

Serving more than 5,500 patients each day, Miraca Life Sciences is a leading, academic-caliber anatomic pathology laboratory, providing diagnostic services in the fields of breast health, dermatology, gastroenterology, hematology and urology. Building on our experience with health IT, we also offer technology solutions and consulting services to assist clinicians and centers with MIPS and other reporting requirements.

Miraca Research & Development Services utilize our expertise and resources as a premier anatomic pathology commercial laboratory. Miraca’s difference is in our ability to draw upon the foundation of our commercial laboratory, to provide pathology, laboratory and data services.

We employ a talented team of leading pathologists, histologists, lab technicians, technology consultants, and other medical professionals — all driven to help provide the highest and most up-to-date levels of diagnostic quality, enhanced workflow and practice solutions possible. It’s part of our commitment: not only to scientific excellence, but to you.

Pathology Research & Publications

Our skilled team of field-specific clinical pathologists, consultants and experts work diligently to stay at the forefront of the ever-changing landscape of a pathology laboratory and health IT. As part of this diligence, we work closely with one another to provide the highest quality, academic-based research and information possible.

Recent News


October 16, 2017

Renflexis™ is Latest Addition to Therapeutic Drug Monitoring by Miraca Life Sciences

IRVING, Texas, October 16, 2017 — Miraca Life Sciences, the largest U.S. independent anatomic pathology laboratory, continues to expand in clinical pathology: its InformTx™ therapeutic drug monitoring (TDM) has begun the validation process for Renflexis™ (infliximab-abda), a biosimilar of Remicade® (infliximab). Testing will be commercially available in early November. Since launching the InformTx service in June 2016, Miraca Life Sciences […]

Continue reading


October 3, 2017

Biocept and Miraca Life Sciences Enter Into Marketing Agreement to Expand Target Selector Testing in the United States

MLS to market Biocept’s proprietary liquid biopsy testing platform in key sales territories, with potential to expand the agreement in the future

SAN DIEGO (October 3, 2017) – Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it has entered […]

Continue reading


We appreciate everything our Miraca team does for us.
— Sherry Auffant, Office Manager, Amy A. Vaughan Dermatology PLLC
Barboursville, W.Va.


READ MORE

Featured Subspecialty Expert


Cristian I. Robiou, MD

Director of Medical Quality Assurance

more